Immune Modulation Stack
Thymic function restoration with gut and inflammatory support.
Thymosin Alpha-1 is the primary thymic peptide for immune T-cell maturation and has been clinically used in hepatitis B/C and cancer adjunct protocols. Combined with KPV and Larazotide for gut barrier integrity, this stack addresses immune function from three angles.
What's in this stack
Research Protocol
- Thymosin Alpha-1: 1.5 mg subcutaneous twice weekly
- KPV: 500 mcg oral daily
- BPC-157: 250 mcg twice daily
Ready to start your Immune Modulation Stack research?
Each compound ships COA-verified, >98% purity, cold-packed for stability.
Frequently Asked Questions
What is KPV and how does it modulate inflammation?
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal of alpha-MSH. It inhibits NF-κB signalling and pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) and has been studied in gut inflammatory models including IBD and colitis.
How does Thymosin Alpha-1 differ from Thymulin?
Thymosin Alpha-1 is a 28-amino acid peptide that enhances T-cell maturation and innate immune signalling via TLR pathways. Thymulin is a zinc-dependent nonapeptide produced in the thymus that specifically drives T-cell differentiation, declining significantly with age.
Are immune peptides suitable for long-term research protocols?
KPV and ARA-290 have been studied in chronic administration models. AICAR has primarily been used in acute metabolic research. Protocol length varies significantly by compound, consult published literature for each specific agent.
Which immune peptides are available in capsule format?
KPV (4 mg), Thymosin Alpha-1 (10 mg), and MOTS-c (10 mg) are available as capsules at Rainbow Peptide, allowing oral administration research without reconstitution.
For research use only. Not intended for human consumption. Must be 18+.